Loestrin 24 Fe Ad Campaign Targets Consumers Not Currently On Birth Control
This article was originally published in The Pink Sheet Daily
Executive Summary
Ads for Warner Chilcott’s 24-day oral contraceptive debuted May 15, directing consumers to studies demonstrating a shorter period duration.
You may also be interested in...
Berlex’ YAZ Clears FDA For Contraception; April Launch Planned
A premenstrual dysphoric disorder indication for the low-dose version of Yasmin is still pending.
Loestrin 24 Approved As First 24-Day Oral Contraceptive
Warner Chilcott beats out Berlex' Yaz as the first oral contraceptive approved in the U.S. with 24 active hormone days.
Lilly's Tirzepatide Shows Up Novo's Ozempic In Head-To-Head Diabetes Trial
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: